Orion
Srikanta Dana is a Senior Scientist at Orion Corporation since April 2021, following a position as a TGen Postdoctoral Fellow at the Translational Genomics Research Institute from February 2019 to April 2021, where focus included medicinal chemistry and hit to lead optimization. Prior to TGen, Srikanta served as a Postdoctoral Research Fellow at the University of Utah College of Pharmacy, specializing in DNA-Encoded Chemical Library Technology from October 2016 to February 2019. Srikanta's early career includes extensive research experiences at Jawaharlal Nehru University from January 2009 to September 2016, with roles as Research Associate, Senior Research Fellow, Junior Research Fellow, and Research Fellow, encompassing areas such as chemical biology, molecular biology, medicinal chemistry, and organic synthesis. Educational qualifications include a Postdoctoral Research Fellowship in DNA-Encoded Chemical Library Technology from the University of Utah, a Ph.D. in Chemical Biology, Organic Synthesis, and Molecular and Cell Biology from Jawaharlal Nehru Vishvavidyalaya, and a Master of Science in Applied Chemistry from IIEST, Shibpur.
Orion
1 followers
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.